DERMATOMYOSITIS
Clinical trials for DERMATOMYOSITIS explained in plain language.
Never miss a new study
Get alerted when new DERMATOMYOSITIS trials appear
Sign up with your email to follow new studies for DERMATOMYOSITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for myositis patients: long-term drug safety trial underway
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called efgartigimod for adults with a group of muscle diseases known as idiopathic inflammatory myopathy (IIM). Only people who completed an earlier study of this drug can join. Participants will receive the drug for up to 51 mon…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 17, 2026 07:57 UTC
-
Early IVIg boost may tame muscle disease before it disables
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis leads to better improvement than steroids alone. Myositis causes muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past year with ce…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated May 17, 2026 07:56 UTC
-
New drug hope for rare muscle disease
Disease control OngoingThis study tests a new medicine called empasiprubart against a placebo in adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. About 3 participants will receive the drug or placebo for 25 weeks, then be followed for safety over a year. The goal is …
Matched conditions: DERMATOMYOSITIS
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New pill could tame rare Muscle-Skin disease
Disease control OngoingThis study tests an oral medication called brepocitinib in 241 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The drug aims to reduce disease activity over 52 weeks. Participants are randomly assigned to receive one of two doses or a placebo,…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Promising skin drug trial for rare muscle disease pulled before start
Disease control TerminatedThis study aimed to test deucravacitinib, a pill already approved for psoriasis, in adults with dermatomyositis or juvenile dermatomyositis that did not respond to standard treatments. The goal was to see if the drug could improve muscle and skin symptoms. However, the study was …
Matched conditions: DERMATOMYOSITIS
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
New oral drug shows promise for rare muscle disease
Disease control OngoingThis study tests an experimental daily pill called GLPG3667 in 40 adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. The goal is to see if the drug can reduce disease activity over 24 weeks compared to a placebo. Participants will then have the opt…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE2 • Sponsor: Galapagos NV • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New study aims to uncover hidden cancer triggers in rare muscle disease
Knowledge-focused OngoingThis study looks at blood samples from 50 adults with dermatomyositis, an autoimmune disease that affects muscles and skin and raises cancer risk. Researchers want to find new antibodies and immune markers that could help tell which patients are more likely to develop cancer. The…
Matched conditions: DERMATOMYOSITIS
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC